Unclaimed Scholar Profile
Are you Dirk Jacobus Blom? This profile has been curated from verified academic registries. Claim your profile to edit affiliations, manage works, and access your dashboard.
Verified ScholarVerified at University of Cape TownASIDASID-6579-5376-0112 orcid.org/0000-0003-3965-5912
Dirk Jacobus Blom
University of Cape Town•South Africa
Faculty researcher at University of Cape Town (ZA), specializing in Social Sciences & Humanities. [Discipline: Social Sciences & Humanities] [Scholar Type: Journal Research Scientist] [Career Tier: Distinguished Scholar] [Region: Southern Africa]
#Lipoproteins and Cardiovascular Health#Lipid metabolism and disorders#Cholesterol and Lipid Metabolism#Diabetes#Cardiovascular Risks#and Lipoproteins
Scholarly Profiles: Google Scholar
Citation Indices
Standard Scientometrics| All | Since 2021 | |
|---|---|---|
| Citations | 17,930 | 8,606 |
| h-index | 51 | 38 |
| i10-index | 106 | 74 |
Annual Citation Growth
Verified Citations / Year0
2020861
2021+40%1.2k
2022+29%1.5k
2023+33%2.1k
2024-8%1.9k
2025-45%1.0k
2026Scholarship Distribution & Proportions226 Articles • 0 Books & Monographs • 0 Applied Assignments
Continental Provenance:82% African Regional Citations (14,703) • 18% Global Research Impact (3,227)
226 Indexed WorksAuthentic Data
Co-Authors & Academic Collaborators
No verified co-authors registered on AfriJournal Index yet.
Browse African Scholars →Scientific Bibliography Ingestion Notice
AfriJournal Index synchronizes authentic African citations and scholarship from Crossref, OpenAlex, and verified institutional repositories. Due to external indexing latency, some historical works may not yet be ingested in this snapshot. If you are this scholar, claim this profile to link your ORCID and verify your complete bibliography.
Articles & Books (226)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Published in The Lancet•2019
DOI: 10.1016/s0140-6736(19)31149-3 Verified Peer-Reviewed
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Published in New England Journal of Medicine•2015
DOI: 10.1056/nejmoa1500858 Verified Peer-Reviewed
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
Published in The Lancet•2010
DOI: 10.1016/s0140-6736(10)60284-x Verified Peer-Reviewed
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
Published in LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)•2022
DOI: 10.1056/nejmoa2210645 Verified Peer-Reviewed
Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study
Published in The Lancet•2012
DOI: 10.1016/s0140-6736(12)61731-0 Verified Peer-Reviewed
Showing 1 – 5 of 226 publications
1 / 46